tert-Butyl 4-((5-(methoxycarbonyl)-1-methyl-1h-pyrazol-3-yl)oxy)piperidine-1-carboxylate

Catalog No. :
ACEWRA096
CAS No. :
1404364-80-2
Molecular Formula :
C16H25N3O5
Molecular Weight :
339.39

IUPAC Name:tert-butyl 4-((5-(methoxycarbonyl)-1-methyl-1H-pyrazol-3-yl)oxy)piperidine-1-carboxylate

tert-Butyl 4-((5-(methoxycarbonyl)-1-methyl-1h-pyrazol-3-yl)oxy)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$425.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-((5-(methoxycarbonyl)-1-methyl-1h-pyrazol-3-yl)oxy)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-((5-(methoxycarbonyl)-1-methyl-1H-pyrazol-3-yl)oxy)piperidine-1-carboxylate
MDL No.MFCD21332850
Molecular FormulaC16H25N3O5
Molecular Weight339.39
SMILESO=C(OC(C)(C)C)N1CCC(CC1)OC2=NN(C(C(OC)=O)=C2)C
InChI KeyGICJPZSCRXHGJH-UHFFFAOYSA-N
Synonym1-Piperidinecarboxylic acid, 4-[[5-(methoxycarbonyl)-1-methyl-1H-pyrazol-3-yl]oxy]-, 1,1-dimethylethyl ester
CAS No.1404364-80-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACEWRA096 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACZCAF087 route compound structure diagram
    ACZCAF08752867-42-2 In Stock
  4. Then
  5. ACEWRA096 route product structure diagram
    ACEWRA0961404364-80-2
Inquiry

2. ACEWRA096 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACZCAF087 route compound structure diagram
    ACZCAF08752867-42-2 In Stock
  4. Then
  5. ACEWRA096 route product structure diagram
    ACEWRA0961404364-80-2
Inquiry

Comments (0)